Journal
MEDICAL CLINICS OF NORTH AMERICA
Volume 97, Issue 3, Pages 377-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2012.12.017
Keywords
Alzheimer disease; Amyloid imaging; Posistron emission tomography; A beta levels
Categories
Funding
- National Health and Medical Research Council of Australia [1011689]
- Science and Industry Endowment Fund
- Austin Hospital Medical Research Foundation
Ask authors/readers for more resources
In vivo imaging of amyloid-beta (A beta) with positron emission tomography has moved from the research arena into clinical practice. Clinicians working with cognitive decline and dementia must become familiar with its benefits' and limitations. Amyloid imaging allows earlier diagnosis of Alzheimer disease and better differential diagnosis of dementia and provides prognostic information for mild cognitive impairment. It also has an increasingly important role in therapeutic trial recruitment and for evaluation of anti-A beta treatments. Longitudinal observations are required to elucidate the role of A beta deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available